ARS Pharmaceuticals Key Ratios

$6.03

$0.00 (0.00%)

As on 27-Aug-2026 16:00EDT

Market cap

info icon

$547 Mln

Revenue (TTM)

info icon

$117 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

43.8

Div. Yield

info icon

0 %

Key Ratios and Highlights

Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -60,469.21-36,881.76-180.11-200.269.29
Net Margin info ---1,613.12-184.24----
Return on equity info -36.88-10.00-339.88-92.333.28
Return on Capital info -30.526.99---73.293.28
Return on Assets info -22.95-27.03-52.54-50.472.74
Debt to Equity (x) info ----0.000.840.00
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
--
--
-73.29
3.28
-21.56
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-339.88

Lower than Peers by 299.59

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
-339.88
-339.88
-92.33
3.28
-21.59
Peer Median
-40.29
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-52.54

Lower than Peers by 21.70

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
-52.54
-52.54
-50.47
2.74
-21.13
Peer Median
-30.84
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-180.11

Lower than Peers by 97.89

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
-180.11
-180.11
-200.26
9.29
-181,216.67
Peer Median
-82.21
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-184.24

Lower than Peers by 94.36

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
-184.24
-184.24
-203.25
8.97
-181,216.67
Peer Median
-89.88
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Higher than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
0.00
0.00
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

4.08

Lower than Peers by 49.95

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
4.08
4.08
-0.05
2,970.63
-0.98
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-341.22

Lower than Peers by 340.27

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
-341.22
-341.22
-2,136.92
115.24
-56.75
Peer Median
-0.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-7.94

Lower than Peers by 0.76

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
-7.94
-348.66
-2,241.76
114.71
-56.75
Peer Median
-7.19
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-344.10

Lower than Peers by 358.53

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
-344.10
-344.10
-22.28
1.14
-0.53
Peer Median
14.43
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-93.56

Lower than Peers by 83.10

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
-93.56
-93.56
--
--
--
Peer Median
-10.46
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
--
--
0.84
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
--
--
0.01
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

3.48

Lower than Peers by 2.33

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
3.48
3.48
7.28
14.26
96.85
Peer Median
5.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.28

Lower than Peers by 2.41

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
3.28
3.28
7.06
14.04
96.85
Peer Median
5.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-27.66

Lower than Peers by 25.57

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
-27.66
-27.66
-64.94
--
--
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

40.06

Higher than Peers by 21.08

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
40.06
40.06
31.26
10.28
2,650.00
Peer Median
18.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.29

Higher than Peers by 0.22

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
0.29
0.29
0.25
0.31
0.00
Peer Median
0.07
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
--
--
76.95
20.40
10,981.85
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
--
--
121.44
46.30
-2,524.23
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
--
--
139.45
94.43
6,049.14
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
--
--
58.94
-27.73
2,408.48
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
--
--
-6.70
129.21
-9.69
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

43.75

Higher than Peers by 38.40

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
43.75
43.75
10.05
4.02
2.28
Peer Median
5.35
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-9.88

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
-9.88
-9.88
-5.97
86.01
-5.50
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

547

Higher than Peers by 400

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
ARS Pharmaceuticals
547
547
--
--
--
Peer Median
147
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...